Viatris Inc. (VTRS) Income Statement

The 10-quarter trend shows revenue oscillating between $3.3B and $3.8B, with year-over-year growth ranging from -11.2% in 2025Q1 to +8.1% in 2026Q1. The recent positive growth in 2026Q1 and Q2 may reflect the divestiture of the Biosimilars business, which removed a high-growth but capital-intensive segment, leaving a more stable, albeit slower, base. However, the underlying erosion of legacy brands and the expansion of China's VBP program suggest that this growth is unlikely to be sustained without new product launches or acquisitions.

The gross margin decline in 2025Q4 to 30.6% was likely driven by one-time inventory step-up charges or product mix, but the recovery to 38.8% in 2026Q2 suggests some stabilization. Compared to peers like Teva (51.8%) and Amneal (37.6%), Viatris's gross margin is below the innovative pharma level but above commodity generics, reflecting its branded-generic mix. The ongoing China VBP expansion directly threatens the high-margin branded segment, which could compress gross margins further if not offset by cost reductions or new complex generics.

The negative operating income in several quarters, particularly the -$2.9B in 2025Q1, appears to be driven by impairment charges and restructuring costs rather than operational inefficiency. However, even in quarters with positive operating income, the margins are thin (0.2% to 6.7%), suggesting that SG&A and R&D expenses are not scaling down proportionally with revenue declines. The company's high fixed-cost base, including its global manufacturing footprint, limits operating leverage, and investors should watch whether the strategic review leads to further cost rationalization.

The COGS-to-revenue ratio has ranged from 58.9% to 69.4%, with the highest in 2025Q4, suggesting that input costs or inventory write-downs have pressured gross margins. SG&A has been relatively flat, even as revenue has declined, which has contributed to negative operating leverage. R&D spending has increased slightly from $199.7M in 2024Q1 to $248.3M in 2026Q2, indicating a continued investment in complex generics, but this has not yet translated into meaningful revenue growth. Management's expense discipline appears to be focused on SG&A, but the lack of significant reduction in COGS suggests that the manufacturing footprint is not being optimized.

The massive loss in 2025Q1 was likely due to the write-down of the Biosimilars business and other assets, which led to the divestiture to Biocon Biologics. This event marked a shift from a diversified growth strategy to a more focused, mature value approach, with management raising guidance in 2026Q2. The lasting impact is a leaner portfolio with lower growth but potentially higher cash flow, as the company reduces debt and returns capital to shareholders. However, the success of this inflection depends on whether the remaining branded-generic business can sustain its margins in the face of China VBP and US generic pricing pressure.